FY2026 EPS Forecast for Aktis Oncology Decreased by Analyst

Aktis Oncology (NASDAQ:AKTS – Free Report) – Research analysts at HC Wainwright lowered their FY2026 earnings per share estimates for Aktis Oncology in a note issued to investors on Friday, November 13th. HC Wainwright analyst R. Burns now forecasts that the technology company will post earnings per share of ($1.97) for the year, down from their prior estimate of ($1.64). The consensus estimate for Aktis Oncology’s current full-year earnings is ($1.94) per share. HC Wainwright also issued estimates for Aktis Oncology’s Q4 2026 earnings at ($0.60) EPS, Q1 2027 earnings at ($0.63) EPS, Q2 2027 earnings at ($0.66) EPS, Q3 2027 earnings at ($0.70) EPS, Q4 2027 earnings at ($0.73) EPS and FY2027 earnings at ($2.73) EPS.

A number of other brokerages have also issued reports on AKTS. Wedbush restated an “outperform” rating and set a $35.00 target price on shares of Aktis Oncology in a research report on Friday, October 2nd. Weiss Ratings cut Aktis Oncology from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, November 13th. Wall Street Zen lowered shares of Aktis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Raymond James Financial reissued a “strong-buy” rating on shares of Aktis Oncology in a research note on Tuesday. Finally, BMO Capital Markets started coverage on shares of Aktis Oncology in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Aktis Oncology currently has an average rating of “Moderate Buy” and an average price target of $35.62.

View Our Latest Stock Report on Aktis Oncology

Aktis Oncology Price Performance

Shares of AKTS opened at $16.10 on Tuesday. Aktis Oncology has a fifty-two week low of $13.96 and a fifty-two week high of $34.19. The company’s 50-day moving average is $17.99 and its 200-day moving average is $20.73.

Aktis Oncology (NASDAQ:AKTS – Get Free Report) last issued its earnings results on Thursday, November 12th. The technology company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.07). The firm had revenue of $3.91 million for the quarter, compared to analyst estimates of $4.87 million. Aktis Oncology had a negative return on equity of 26.86% and a negative net margin of 706.81%.

Institutional Investors Weigh In On Aktis Oncology

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. lifted its stake in Aktis Oncology by 7.9% in the 2nd quarter. BlackRock Inc. now owns 2,278,358 shares of the technology company’s stock worth $73,431,000 after purchasing an additional 166,231 shares in the last quarter. Blue Owl Capital Holdings LP raised its holdings in shares of Aktis Oncology by 8.9% during the 3rd quarter. Blue Owl Capital Holdings LP now owns 3,343,827 shares of the technology company’s stock valued at $65,104,000 after buying an additional 273,608 shares in the last quarter. Wellington Management Group LLP bought a new stake in shares of Aktis Oncology in the 2nd quarter worth approximately $63,372,000. Jupiter Topco LLC purchased a new stake in Aktis Oncology during the second quarter valued at about $42,359,000. Finally, State Street Corp grew its position in Aktis Oncology by 8.5% during the 3rd quarter. State Street Corp now owns 1,050,480 shares of the technology company’s stock worth $20,453,000 after acquiring an additional 82,460 shares during the last quarter. 28.84% of the stock is currently owned by institutional investors.

Aktis Oncology Company Profile

(Get Free Report)

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.

Read More

Earnings History and Estimates for Aktis Oncology (NASDAQ:AKTS)

Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.